Opendata, web and dolomites

ERA4TB SIGNED

EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ERA4TB project word cloud

Explore the words cloud of the ERA4TB project. It provides you a very rough idea of what is the project "ERA4TB" about.

trials    formulation    progress    hollow    ending    decision    combination    vitro    models    imaging    execute    dynamic    tests    murine    regimen    compounds    diabetes    accelerator    outcome    drug    treat    agile    monitor    unavailable    primate    era4tb    strategy    artificial    extensive    tolerated    comprising    candidates    ranking    aids    leads    first    pk    evaluation    tools    regimens    assembled    combinations    aided    algorithm    shortening    pharmacological    efpia    entails    ct    un    exposure    flexible    bioavailable    pet    assays    safe    therapy    intelligence    ready    expertise    active    negligible    starting    enter    predict    comorbidities    tb    preclinical    doses    construction    simulation    time    clinical    biomarker    20    fiber    molecules    tuberculosis    human    portfolio    combined    hiv    orally    bactericidal    disease    cell    innovative    points    sustainable    profiling    series    characterisation    pd    invasive    compatible    progression    2030    forms    single    treatment    constitute    drugs    details    nir    discovery    interactions    explicit   

Project "ERA4TB" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD CARLOS III DE MADRID 

Organization address
address: CALLE MADRID 126
city: GETAFE (MADRID)
postcode: 28903
website: http://www.uc3m.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 207˙963˙991 €
 EC max contribution 89˙815˙600 € (43%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-15-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2025-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD CARLOS III DE MADRID ES (GETAFE (MADRID)) coordinator 5˙804˙800.00
2    FONDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS (IM4TB) CH (LAUSANNE) participant 22˙407˙250.00
3    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 16˙997˙500.00
4    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 12˙003˙900.00
5    UNIVERSIDAD DE ZARAGOZA ES (ZARAGOZA) participant 4˙247˙900.00
6    CRITICAL PATH INSTITUTE, LIMITED IE (DUBLIN) participant 3˙557˙500.00
7    INSTITUT PASTEUR DE LILLE FONDATION FR (LILLE) participant 2˙853˙750.00
8    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 2˙443˙750.00
9    FORSCHUNGSZENTRUM BORSTEL DE (BORSTEL) participant 2˙287˙500.00
10    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 2˙012˙500.00
11    BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE FR (LYON) participant 1˙856˙250.00
12    UPPSALA UNIVERSITET SE (UPPSALA) participant 1˙797˙500.00
13    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 1˙677˙500.00
14    SCIENSANO BE (ELSENE) participant 1˙637˙500.00
15    Department of Health UK (Leeds) participant 1˙557˙500.00
16    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 1˙407˙500.00
17    GRITSYSTEMS AS DK (VALBY) participant 1˙132˙500.00
18    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 962˙500.00
19    IMABIOTECH SAS FR (LOOS) participant 837˙500.00
20    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 615˙000.00
21    UNIVERSITA DEGLI STUDI DI PAVIA IT (PAVIA) participant 592˙000.00
22    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE UK (MANCHESTER) participant 293˙500.00
23    LATVIJAS ORGANISKAS SINTEZES INSTITUTS LV (RIGA) participant 277˙500.00
24    LUNDS UNIVERSITET SE (LUND) participant 277˙500.00
25    QPS NETHERLANDS BV NL (GRONINGEN) participant 277˙500.00
26    BILL & MELINDA GATES FOUNDATION US (SEATTLE, WASHINGTON) participant 0.00
27    EVOTEC INTERNATIONAL GMBH DE (HAMBURG) participant 0.00
28    GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL ES (TRES CANTOS) participant 0.00
29    GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION US (NEW YORK) participant 0.00
30    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
31    UNIVERSITY OF DUNDEE UK (DUNDEE) participant 0.00

Map

 Project objective

The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided by EFPIA. Since details of these are as yet unavailable, we will implement an agile drug development algorithm that entails profiling and portfolio construction. Profiling involves characterisation and ranking molecules in preclinical studies comprising in vitro drug combination assays, hollow fiber and single cell analysis, innovative murine and non-human primate models, PK/PD studies, combined with biomarker discovery and non-invasive NIR or PET/CT imaging to monitor disease progression and response to treatment. Modelling, simulation and artificial intelligence tools will help progress compounds from early preclinical to clinical development and to predict drug exposure, human doses and the best combinations. After extensive preclinical profiling, selected compounds will enter portfolio development for first time in human tests and phase I clinical trials in order to ensure that they are safe, well-tolerated and bioavailable with negligible drug-drug interactions. If needed, formulation studies will be conducted to improve pharmacological properties. ERA4TB has assembled the best expertise and resources available in Europe, to build a highly effective and sustainable drug development consortium with a flexible and dynamic management system to execute the profiling and portfolio strategy, aided by clearly defined go/no-go decision points. The expected outcome of ERA4TB is a series of highly active, bactericidal, orally available drugs to constitute two or more new combination regimens with treatment-shortening potential ready for Phase II clinical evaluation. These regimens will be compatible with drugs used to treat common comorbidities, such as HIV-AIDS and diabetes, and should impact UN Sustainable Development Goal 3, namely, ending TB by 2030.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ERA4TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ERA4TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More